After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?
Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.
Overview
Shares of vaccine maker Moderna (NASDAQ: MRNA) have been rallying this year, and at one point, they were up more than double where they started the year. Growth investors appear to be encouraged by the company's long-term prospects and its promising flu vaccines.
While the rally may seem exciting, here's why I don't think it's destined to last. Moderna's stock, while volatile, remains high-risk.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Five Star Bancorp Director Larry Allbaugh Buys $4.3 Million in Shares. What Does This Mean for Investors?
- AT&T Stock Has Been Quietly Rallying Since the Start of July. After a Strong Q2, Is It Due to Soar Even Higher?
- Student loan default is rising: 3 ways to start paying down your balance — even on a tight budget
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.